Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.

MULTI-CENTER,DOUBLE-BLIND, RANDOMIZED, TWO-ARMS, CONTROLLED, PROSPECTIVE CLINICAL INVESTIGATION ASSESSING THE SAFETY AND PERFORMANCE OF A CLASS IIb MEDICAL DEVICE (CLEARPLASMATM) FOR THE TREATMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL HEMORRHAGE.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04174989

Enrollment

Registered

2019-11-22

Start date

2020-10-24

Completion date

2022-11-13

Last updated

2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Upper Gastrointestinal Bleeding, Acute Upper Gastrointestinal Hemorrhage

Keywords

Acute Upper Gastrointestinal Hemorrhage, Gastrointestinal Hemorrhage, Gastrointestinal Bleeding, Acute Upper Gastrointestinal Bleeding, Plasminogen-Depleted Plasma, Plasma Transfusion

Brief summary

Pre-market, multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation of a Class IIb Investigational Medical Device, in which Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of plasminogen-depleted plasma (PDP) or fresh-frozen plasma (FFP). In case of transfusions needing more than two units, the third unit and above will consist in regular plasma for both treatment groups. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30+/-3 days after transfusion.

Detailed description

Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive hemodynamic resuscitation, prevention and treatment of complications and treatment of bleeding, which generally includes endoscopic intervention and transfusion of appropriate blood components. However, in many cases, spontaneous hyperfibrinolysis occurs, jeopardizing pharmacological control of AUGIH. Antifibrinolytic drugs are considered effective in counteracting hyperfibrinolysis, but are associated with various side effects, such as neurotoxicity and accelerated fibrinolysis upon prolonged use. Fibrin clot breakdown is actively mediated by plasmin, a serine protease which cleaves fibrin. Administration of plasma depleted of plasminogen, the precursor of plasmin, may shift the balance towards coagulation. PlasFree Ltd. has developed ClearPlasma, a single-use, extracorporeal plasma filtration device which extracts plasminogen from plasma to reduce fibrinolysis. The resulting plasminogen-depleted plasma (PDP) is expected to reduce risk of fibrinolysis and re-bleeding in Patients undergoing plasma transfusions. The Primary Objective of this trial is to assess the safety profile of a one-time infusion of up to two units of PDP obtained through filtration with ClearPlasma in Patients presenting with acute upper gastrointestinal hemorrhage and to compare it to the same procedure carried out using FFP units. The Secondary Objective of this trial is to assess the efficacy of a one-time infusion of up to two units of PDP obtained through filtration with ClearPlasma in the reduction of re-bleeding in Patients presenting with acute upper gastrointestinal hemorrhage (as a measure of the performance of ClearPlasma) and to compare it to the same procedure carried out using FFP units.

Interventions

OTHERPlasma treated with ClearPlasma (Extra-corporeal plasma filtration device)

ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.

OTHERRegular fresh-frozen plasma (not treated)

Regular fresh-frozen plasma (not treated)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Masking description

An unblinded sub-Investigator will prepare the plasma bags to be used for treatment (PDP or FFP). The randomization will be carried out in accordance to the the instructions provided, keeping the Investigator's and Patient's blindness about the content of plasma bags used for transfusion of participants.

Intervention model description

Multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation, in which Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and required plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP (group A) or FFP (group B). The administration of Plasma needs to be in line with the clinical practice and doctor decision.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female Patients. 2. Patients aged ≥ 18 and ≤ 80 years old. 3. Patients presenting with acute upper gastrointestinal hemorrhage (\> 0.5 L), diagnosed by presence of blood in gastric lavage, hematemesis or melena within no longer than 24 h before enrolment. 4. Patients presenting with acute upper gastrointestinal hemorrhage (\< 24 h) for which fresh frozen plasma (FFP) has been ordered. 5. Patients understanding the nature of the study and providing their informed consent to participation. 6. Patients willing and able to attend the follow-up visits and procedures foreseen by study protocol.

Exclusion criteria

1. Patients who underwent a plasma infusion in the 30 days before enrolment. 2. Patients in a life-threatening condition at the time of enrolment. 3. Patient on anticoagulant therapy at the time of enrolment. 4. Patients with known renal failure (creatinine clearance \< 30 mL/min) at the time of enrolment. 5. Patients suffering of Hemophilia A or B. 6. Patients suffering of venous and arterial thromboembolic events within 3 months before the enrolment. 7. Patients with history of allergic reaction to plasma, polyethersyplone or polycarbonate. 8. Patients suffering of IgA deficiency at the time of enrolment. 9. Patients with history of hemorrhage while on anticoagulant treatment (warfarin, apixaban, rivaroxaban, dabigatran, low molecular weight heparin). 10. Patients identified by the Investigator to have any underlying medical conditions that may preclude conduct of study procedure (i.e. making the administration of study treatment hazardous) or obscure the interpretation of safety objectives. 11. Patients who are participating or have participated in other clinical studies within the 30 days before the study enrolment. 12. Women who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical investigation and for 3 months later. 13. Female Patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception \*. * Methods at low risk of contraceptive failure (less than 1% per year) when used consistently, including: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), some intra-uterine devices.

Design outcomes

Primary

Measure	Time frame	Description
Safety Profile in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of adverse events rate during the study period and within 30±3 days after transfusion with PDP (group A) or FFP (group B). All adverse occurrences (serious/non-serious or device-related/non-device related) will be recorded prospectively, categorized and evaluated for causality using defined criteria.

Secondary

Measure	Time frame	Description
Duration of hospital stay in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient) or until patient discharge.	Comparison of the duration of the hospital stay for the Patient up to 30±3 days after transfusion with PDP (group A) or FFP (group B).
CBC profile in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of complete blood count (CBC) profiles between Patients who received transfusion with PDP (group A) or FFP (group B) at baseline (Screening Visit) versus T=8-12h, T=24-48h and End of Study Visit.
D-dimer profile in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of D-dimer profiles between Patients who received transfusion with PDP (group A) or FFP (group B) at baseline (Screening Visit) versus T=8-12h, T=24-48h and End of Study Visit.
PT/INR (blood coagulation parameter) measurement in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient) or until patient discharge.	Comparison of Prothrombin Time and International Normalized Ratio (PT/INR) between Patients who received transfusion with PDP (group A) or FFP (group B) until Patient discharge from hospital.
Incidence of re-bleeding episodes in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of the number of re-bleeding episodes occurring for the Patient throughout the study period and within 30±3 days after transfusion with PDP (group A) or FFP (group B).
Incidence of venous and arterial thromboembolic events in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of the incidence of venous and arterial thromboembolic events during the study period and within 30±3 days after transfusion with PDP (group A) or FFP (group B).
Plasma transfusion-related mortality in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient).	Comparison of the plasma transfusion-related mortality during the study period and within 30±3 days after transfusion with PDP (group A) or FFP (group B).
Total blood loss from transfusion in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient) or until patient discharge.	Comparison of total blood loss from transfusion with PDP (group A) or FFP (group B) until Patient discharge from hospital, as measured by: 1. Red blood cells (RBC) units transfused; 2. Plasma units transfused; 3. Platelet units transfused; 4. Hemoglobin levels.
aPTT (blood coagulation parameter) measurement in Patients treated with PDP versus FFP.	Entire Study Period (up to 1 month per patient) or until patient discharge.	Comparison of Activated Partial Thromboplastin Time (aPTT) between Patients who received transfusion with PDP (group A) or FFP (group B) until Patient discharge from hospital.

Countries

Czechia, Israel, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026